Xylem Inc.
NYSE:XYLIndustrial - Machinery
+$1.04 today
- Market cap
- $21.83B
- Beta
- 1.04
- P/E (TTM)
- 27.8
- EPS (TTM)
- $4.01
- Dividend yield
- 1.49%
Volume 2.70M
Average 2.15M
XYL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Xylem Inc.NYSE: XYL
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows in line with its trailing trend
Q2 FY2026 research & development of $59M rose 1.7% year over year, ahead of the +0.0% change in trailing-twelve-month research & development. Sequentially, it rose 5.4% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Research & development amounted to 2.5% of revenue in FY2025, down 0.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of +0.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 226M USD
- Year-over-year change
- -1.7%
- 4-year CAGR
- +2.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 226M | -1.7% |
| FY2024 | 2024-12-31 | 230M | -0.9% |
| FY2023 | 2023-12-31 | 232M | +12.6% |
| FY2022 | 2022-12-31 | 206M | +1.0% |
| FY2021 | 2021-12-31 | 204M | — |
Research & Development vs competitors
How XYL compares with its peers on the latest reported figures
- XYL's LTM Jun 2026 research & development of $227M is the 2nd highest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of +0.0% is the 3rd highest of 5, against a peer median of +1.9%.
- Research & development amounts to 2.5% of revenue for XYL, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $276M | +4.9% | +7.0% | 4.8% | |
| LTM Jun 2026 | $227M | +0.0% | +3.1% | 2.5% | |
| LTM Sep 2026 | $94.1M | -1.2% | +1.3% | 2.4% | |
| LTM Jun 2026 | $19.2M | +14.3% | — | 0.7% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | +10.7% | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | +6.2% | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding XYL) | $0 | +1.9% | +6.6% | 0.0% | |
Competitors are the stored peer set for XYL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.2B | 5.52B | 7.36B | 8.56B | 9.04B |
| Cost of Revenue | 3.22B | 3.44B | 4.65B | 5.35B | 5.56B |
| Gross Profit | 1.98B | 2.08B | 2.72B | 3.21B | 3.48B |
| Gross Margin | 38.0% | 37.7% | 36.9% | 37.5% | 38.5% |
| Research & Development | 204M | 206M | 232M | 230M | 226M |
| Selling, General & Admin | 1.18B | 1.37B | 1.76B | 1.91B | 1.92B |
| Operating Expenses | 1.39B | 1.46B | 2.07B | 2.2B | 2.25B |
| Depreciation & Amortization | 245M | 236M | 436M | 562M | 575M |
| EBITDA | 832M | 726M | 1.12B | 1.69B | 1.79B |
| EBITDA Margin | 16.0% | 13.1% | 15.2% | 19.8% | 19.8% |
| Operating Income | 585M | 622M | 652M | 1.01B | 1.22B |
| Operating Margin | 11.3% | 11.3% | 8.9% | 11.8% | 13.5% |
| Interest Income | 7M | 16M | 28M | 28M | 0 |
| Interest Expense | 76M | 50M | 49M | 44M | 29M |
| Other Income / Expenses | (74M) | (182M) | (17M) | 78M | (42M) |
| Income Before Tax | 511M | 440M | 635M | 1.09B | 1.18B |
| Pre-Tax Margin | 9.8% | 8.0% | 8.6% | 12.7% | 13.1% |
| Income Tax Expense | 84M | 85M | 26M | 197M | 231M |
| Net Income | 427M | 355M | 609M | 890M | 957M |
| Net Margin | 8.2% | 6.4% | 8.3% | 10.4% | 10.6% |
| EPS (Basic) | 2.37 | 1.97 | 2.81 | 3.67 | 3.93 |
| EPS (Diluted) | 2.35 | 1.96 | 2.79 | 3.65 | 3.92 |
| Weighted Avg Shares | 180.25M | 180.22M | 216.98M | 242.6M | 243.4M |
| Weighted Avg Shares (Diluted) | 181.53M | 180.98M | 218.18M | 243.5M | 244M |
Xylem Inc.
NYSE:XYL
Intrinsic Alpha fair value
Locked
Current Price
$95.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.